Background Antidepressant treatment failure is a common problem worldwide. In this study, we assess whether or not an important aspect of depression, cognitive impairment, is untreated by antidepressants by studying the eff ect of acute antidepressant treatment on a range of cognitive domains.
Introduction
Major depressive disorder is a leading cause of the global burden of disability and disease, 1 and carries a persistent risk of relapse even during remission. Neither chronic illness features nor treatment response can be predicted by clinical symptoms in the acutely ill state. Rather, data increasingly point to persistent cognitive impairments being related to the eff ect of the illness on quality of life and underlying brain network mechanisms. 2, 3 New medications are also being developed with potential for greater effi cacy for cognition. 4, 5 Therefore, defi nitive characterisation of the eff ects of depression and present treatment on cognition can have rapid implications for guiding optimisation of treatment.
Cognition encompasses a hierarchy of dissociable domains, mediated by distinct neurocircuitry, func tioning in concert to enable people to carry out behaviour. These domains range from high cognitive load functions coordinating several task demands according to abstract rules and goals, to lower cognitive load psychomotor functions that sequence and enact motor responses based on concrete rules and cues. 6 Depression and its treatment can have varying eff ects across these domains. Therefore, to defi nitively understand the eff ects of depression on cognition as a whole or its use as a treatment target, depression needs to be characterised on a wide range of cognitive tests in both the acutely ill and antidepressanttreated states. Unfortunately, the published scientifi c literature is very inconsistent with respect to whether or not successful antidepressant treatment improves cognition, and if so in which domains-an especially important question in light of previous reports implicating poor cognition as a predictor of worse treatment outcomes. [7] [8] [9] Cognitive impairments have been recorded in acute depressive episodes in the domains of episodic memory, verbal memory, and varying subsets of executive function, 10, 11 although some studies instead have reported a more global cognitive impairment across all domains. 12 In terms of the eff ects of treatment, some studies have reported that impairments in executive function generally persist into euthymia 13 but that verbal fl uency improves with clinical remission. 11, 14 By contrast, a recent large meta-analysis reported treatment eff ects most commonly in the domains of verbal memory (a combination of verbal learning or acquisition with verbal recall and memory), working memory, processing speed, and, to a lesser degree, executive function. 15 Importantly, however, in the studies that the metaanalysis was based on, these fi ndings were often not corrected for multiple comparisons, used inconsistent methods, and reported quite small improvements compared with the size of the illness-related impairment. These problems were described as substantial limitations by the authors of the meta-analysis. Other authors have cited additional inconsistencies in the existing scientifi c
Research in context
Evidence before this study We searched PubMed from Jan 1, 1975 , through to Nov 30, 2015, with the terms "cognition", "unipolar depression", and "antidepressant" for articles published in English characterising change in cognitive impairment in unipolar depression with antidepressant treatment. Despite published studies showing overwhelming consensus for the importance of assessment and treatment of cognition in depression, no conclusion has been reached about the full profi le of cognitive domains impaired in unipolar depression, whether this profi le diff ers between acutely ill and euthymic patients, and the eff ect of treatment with typical antidepressants on cognition. Rather, the existing literature is fractured by confl icting fi ndings from small studies using inconsistent methods, examining diff erent subgroups of cognitive domains and often without appropriate controls for multiple comparisons, assessing patients with mild to severe clinical symptoms rather than those in remission, and often focusing only on older adults. Therefore, whether or not cognition is aff ected by treatment with typical antidepressants and whether this diff ers by type of antidepressant or clinical outcome, remain unknown. This major knowledge gap has important clinical implications: no guidelines exist regarding assessment of cognitive impairment in depression or treatment strategies for patients with impaired cognition. What is therefore needed is a defi nitive determination of the eff ects of antidepressants on the entire cognitive profi le associated with depression, across the full non-elderly adult age range (18-65 years).
Added value of this study
To the best of our knowledge, this study is the fi rst large-scale, primary, prospective analysis of cognitive change with typical antidepressant medication treatment. It is also the fi rst study to systematically probe a broad range of cognitive functions, longitudinally, in patients across the full adult age range, allowing a comprehensive determination of the effi cacy of three commonly used antidepressants on the cognitive profi le of depression. Furthermore, we assess the eff ects of both successful and unsuccessful treatment on cognition, compared with a large sample of healthy controls reassessed at the same interval, and do analyses at both the group and individual level. This approach ensures a robust result that is not dependent on analysis method, outcome defi nitions, or the potential for false-positive results common in small studies. Our fi ndings show that at the population level, patients with depression have robust cognitive impairments in attention, response inhibition, verbal memory, decision speed, and information processing, which show no change despite antidepressant treatment when compared with controls tested at the same intervals, and are notably similar irrespective of clinical remission. Other cognitive domains (executive function and cognitive fl exibility) do improve over the course of acute treatment. These fi ndings create a robust foundation for understanding previous studies that were not able to assess all domains in the same patient population, adding a characterisation of relative impairments and change across domains. Our fi ndings are also notable for the analysis of the course of cognitive impairments on an individual level, which is rarely done but is of major clinical importance. We found that impairments persist despite treatment in more than 95% of patients and broader cognitive impairments occur in individuals with greater illness chronicity. Importantly, we also add to the literature a comparison across treatments, and report that none of the three commonly used antidepressants tested showed better effi cacy for cognition compared with the others, irrespective of clinical outcome or age.
Implications of all the available evidence Impairments in higher order cognitive operations are representative of trait-like features of depression that commonly used antidepressants do not eff ectively improve in the overwhelming majority of patients, even when clinical remission is achieved. These specifi c cognitive domains are an untreated aspect of depression that probably contributes to high rates of treatment failure and risk of relapse. Our fi ndings therefore support the importance of cognition as an unmet treatment need, and therefore a potential therapeutic target, and highlight the need for careful assessment of cognition in trials of new antidepressants.
literature studying cognition in depression that limit defi nitive conclusions, including small study sizes and variability in cognitive domains assessed, tasks used, task design and reporting, assignment of task impairment to cognitive domain, and clinical assessment methods and criteria. 15 Therefore, a large-scale and systematic investigation of cognition using a standardised test battery is needed to ascertain which cognitive domains, if any, are improved by antidepressant treatment. 16 We sought to address this major knowledge gap by fi rst studying the eff ect of depression on cognition in a well powered sample, and second, by assessing the eff ects of three frequently used antidepressants on cognitive change as a function of clinical treatment outcome. Based on the published literature, we postulated that a subset of cognitive impairments in depression would persist despite acute treatment with conventional antidepressants and attainment of clinical remission-ie, cognition is independent of clinical symptoms.
Methods

Study design and participants
The methods of the International Study to Predict Optimized Treatment in Depression (iSPOT-D) are described in detail elsewhere. 17, 18 Briefl y, this is a multicentre, international, open-label, randomised, prospective trial, measuring change in multiple cognitive and clinical measures in medication-free patients compared with healthy controls.
A complete list of participating institutions and regulations is provided in the original publication of the trial protocol. 17, 18 Eligible participants were adults (aged 18-65 years) with fi rst-onset or recurrent, non-psychotic major depressive disorder or healthy controls matched in age, sex, and years of education. Patients were nonmedicated at the start of the trial (they were either previously untreated or had at least 1 week of medication washout before the start of the trial). The inclusion criteria stipulated that patients had no history of treatment failure to any of the three protocol drugs (escitalopram, sertraline, or venlafaxine extended release [venlafaxine-XR]) and met criteria for single or recurrent non-psychotic major depressive disorder with total score on the 17-item Hamilton Rating Scale for Depression (HRSD-17) less than or equal to 17. Patients were excluded for other psychiatric comorbidities and medical conditions that would interfere with completion of assessments or lead to contraindication to protocol medications. Patients were diagnosed according to DSM-IV criteria and their diagnosis was confi rmed by Mini-International Neuropsychiatric Interview (MINI-Plus). 19 Institutional review board approval was obtained at each clinical site. Every participant received a verbal and written explanation of study aims, methods, and potential risks and benefi ts from investigators, and provided written informed consent.
Randomisation and masking
Participants were randomly assigned 1:1:1 to antidepressant treatment with escitalopram, sertraline, or venlafaxine-XR, using a blocked randomisation procedure (block size of 12 ). An open-label study design was used to match clinical practice and to ensure safety, with treatment managed by usual care clinicians who did not participate in study ratings. Clinically trained study coordinators supervised by clinically qualifi ed investigators carried out ratings masked to both patient treatment and cognitive performance.
Procedures
Clinic visits for all patients took place at study clinical sites (including academic settings and clinical practices) at week 0 (pretreatment) and week 8 (posttreatment) and included an interview with a study coordinator who used the HRSD-17 and the self-report 16-item Quick Inventory of Depression Sympto matology (QIDS-SR16) to assess each patient's severity of depressive symptoms. Additionally, the QIDS-SR16 was administered via self-report assessments using standardised web-based infrastructure at clinical sites at 1, 2, 4, and 6 weeks into treatment. Since some of the discrepancies in the published literature are attributed to use of diff erent assessments of clinical remission, we did our analysis using these two diff erent assessments to defi ne clinical remission, which enabled us to ask whether our fi ndings would diff er depending on the defi nition of clinical remission used.
Antidepressant medication dosing was adjusted by the usual treating clinicians according to standard clinical practice. The mean dose of each treatment given to the patients was 12·3 mg per day (range 5-20 mg) for escitalopram, 61·1 mg per day (range 12·5-200 mg) for sertraline, and 83·4 mg per day (range 18·75-225 mg) for venlafaxine-XR. 18 Clinical remission was defi ned by an HRSD-17 score less than or equal to 7 or a QIDS-SR16 score less than or equal to 5. Cognitive testing was done with the IntegNeuro battery, derived from and validated against well established neuropsychological constructs, 20 and delivered at the pretreatment timepoint (week 0) and at week 8 as parallel versions through a computerised infrastructure allowing standardised acquisition. Nine cognitive domains were tested at each timepoint, which were chosen to cover a gradient of increasing cognitive load and complexity. These domains were: attention (1-back continuous performance test); response inhibition (go-no go task); verbal memory (verbal interference task); executive function (Austin maze); cognitive fl exibility (Stroop task); working memory (forward digit span); decision speed (choice reaction time); information processing (switching of attention between numbers and letters in a trails A and B task); and motor coordination (fi nger tapping). In total, the computerised task battery took around 40 min to complete, and is used in patients with depression, 9 and in cognitively impaired patient groups with schizophrenia 21 and distractible groups with attention-defi cit hyperactivity disorder (ADHD).
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Outcomes
We measured changes in performance in patients with depression after 8 weeks of treatment with one of the three antidepressants compared with the healthy controls who were retested at the same interval with no other intervention. Second, we analysed change in cognitive performance across domains in the subset of patients whose clinical symptoms remitted with treatment, compared with healthy controls tested during the same intervals and patients with depression whose symptoms did not remit. We assessed changes in cognition both across the group as a whole and at the individual level (to ensure that group eff ects were not countered or driven by a subpopulation of patients). We postulated that the eff ects on cognition would be similar across the three diff erent treatment groups. We therefore studied the eff ects of treatment group on change in cognitive performance across domains at both the group and individual level. We did additional post-hoc analyses to assess diff erences in clinical severity and chronicity associated with diff erent individual cognitive courses.
Statistical analysis
For each task, we recorded measures of accuracy, reaction time, and task completion time. We created summary-normalised performance indices for each task (appendix pp 1-2). Since our primary analysis compared change in cognitive measures over time and repeat testing, and therefore needed data from both pre-treatment and post-treatment timepoints to assess change, we included only patients who completed both the week 0 and week 8 clinical and cognitive testing in our analysis (712 [71%] of 1008 patients). We used median replacement for outliers, which were defi ned as results that were more than 4 SDs away from the mean, after initial confi rmation that fi ndings are consistent irrespective of whether median replacement or exclusion of outliers is used. Median replacement is done by replacing the outlier value with the value of the median of the group (with the outliers excluded) to avoid introducing skew in the distribution of the variable. To account for the eff ects of time and testretest practice, all our analyses compared the change in cognitive performance in healthy controls against the change in performance in patient groups using repeated measures ANOVAs (at a group level) or reliable change index (on an individual level), or compared the same single timepoint in all groups (eg, week 8 patient group performance is compared with week 8 healthy control performance). We considered inter-individual variability in cognitive change with treatment by assessing individual longitudinal change *Norm score=performance normalised to baseline healthy control group, with negative scores indicating worse performance. 
Role of the funding source
Brain Resource was involved in study design, central coordination, and quality control of the raw data. Brain Resource provided a publication committee to manage preparation of the report and factual check of protocol information. Brain Resource had no role in the acquisition, analysis, or interpretation of the data, nor in the preparation, review, or approval of the report, or the decision to submit for publication. AE had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Between Completers (patients who completed both the week 0 and week 8 clinical and cognitive testing) did not diff er from non-completers in week 0 clinical measures or cognitive scores (p>0·05, two-tailed t test) except in attention (p=0·002, Cohen's d=0·21, two-tailed t test). 316 (94%) of the 336 healthy controls were completers (median replaced, appendix p 1).
We initially looked for evidence of persistent cognitive dysfunction after treatment in the patient group as a whole (appendix p 2). We found no additional improvement in cognitive performance in patients with depression after 8 weeks of treatment beyond the eff ects of time and practice eff ects noted in healthy controls during the same period (repeated measures ANOVA, group × time interactions; table 1). Cognitive performance in patients remained impaired post-treatment at week 8 compared with healthy controls at week 8 in most domains, with eff ect sizes similar to those reported in previous large studies (table 1; appendix). 23 We then analysed the relation of impairments in each cognitive domain to patient factors such as age and subjective cognitive symptoms. Age is not related to cognitive impairment in patients, when studied across the age range of participants (fi gure 1; appendix p 6). Furthermore, subjective measures of concentration and decision making did not correlate with objective performance (appendix p 7).
We then studied whether or not depression-related cognitive dysfunction persisted in the subgroup of patients whose clinical symptoms remitted after 8 weeks of antidepressant treatment. Here, we describe the results of our analysis with remission defi ned according to HRSD-17 scores at week 8, and report similar analyses with remission defi ned according to week 8 QIDS-SR16 scores in the appendix. We compared change in cognitive performance in patients who achieved clinical remission (major depressive disorder [MDD]-remit group) over the course of treatment with change in cognitive performance in healthy controls during the same time interval and retesting procedure. We did this analysis in cognitive domains in which the MDD-remit group showed impairments compared with healthy controls (repeated measures ANOVA, main eff ect of group; table 2). Within these domains, cognitive performance in the MDD-remit group between the two timepoints showed no change above that seen in healthy controls (repeated measures ANOVA, group × time interactions; table 2) in attention, response inhibition, cognitive fl exibility, verbal memory, decision speed, and information processing (fi gure 2). We then compared cognition between the MDD-remit group at post-treatment on week 8 and the healthy control group at week 8. At the post-treatment timepoint, the MDD-remit MDD-remit=patients with depression whose clinical symptoms remit (defi ned by the 17-item Hamilton Rating Scale for Depression). *Norm score=performance normalised to baseline healthy control group, with negative scores indicating worse performance. . Causes of improvement in these two domains cannot be distinguished between eff ects of treatment, placebo, and practice eff ects (which would have to be greater in patients than controls). However, within cognitive fl exibility, the data suggest a benefi t from practice eff ects with retesting in the MDD-remit group because no change in cognitive performance occurred above that found in healthy controls over the 8 weeks and the test-retest procedure.
In summary, although this pattern was not detected in assessment of the patient group as a whole, analysis only of patients with a successful treatment course showed improvement in executive function (in this case, assessed by a visuospatial planning task) and cognitive fl exibility (fi gure 2B). By contrast, even when treatment led to clinical remission, no change occurred in cognitive impairments in attention, response inhibition, verbal memory, decision speed, or information processing. Furthermore, the severity of impairments in these fi ve domains did not diff er signifi cantly between remitters and non-remitters (appendix pp 7-8). These fi ndings remain robust irrespective of whether remission is defi ned by objective (HRSD-17) or subjective (QIDS-SR16) measures of clinical symptoms, or timing of clinical change (appendix pp 8-9, 12).
Next, we assessed treatment group eff ects, to ascertain whether any one of the three antidepressant treatments led to a greater change in cognition than the others during the 8 weeks of treatment and retesting, in either the MDDremit or the MDD-non-remit group. We did not record a signifi cant eff ect of treatment group on changes in cognition in either patient subgroup (repeated measures ANOVA, group × time × treatment; table 3, appendix p 13). Individual drug-level data, specifi cally cognitive change in each domain in MDD-remit and MDD-non-remit groups with each drug, are shown in appendix p 13. Overall, we recorded no change in the course of cognitive symptoms over time, testing, or treatment; this situation remained the same irrespective of antidepressant treatment choice between venlafaxine-XR, escitalopram, or sertraline.
For our evaluation of inter-individual variability in cognitive change with treatment, we assessed individual longitudinal change in cognitive performance. The percentage of patients showing improvement, worsening, or no change in performance in each cognitive domain over the course of treatment is tabulated (appendix p 14). 0·39  0·73  0·001  0·08  0·13  -1·77  0·08  2·99  0·004  0·29  0·08  -1·05  0·28  1·29  0·004 Response inhibition 0·34  0·92  0·001  0·01  0·19  -2·53  0·001 12·14  0·02  0·002 0·24  -3·09  0·16  1·81  0·005   Working  memory   ··  ··  ··  ··  ··  ··  ··  ··  ··  ··  ··  ··  ··  ··  0·61  0·50  0·001   Psychomotor  response  speed   ··  ··  ··  ··  ··  ··  ··  ··  ··  ··  ··  ··  ··  ··  0·41  0·89  0·003 MDD-remit=patients with depression whose clinical symptoms remit (defi ned by the 17-item Hamilton Rating Scale for Depression). *There was no signifi cant diff erence in cognition change in response to treatment and testing paradigm across treatment groups. †Norm score=performance normalised to baseline healthy control group, with negative scores indicating worse performance. 
Discussion
In this report, we present a large-scale and defi nitive study that broadly assesses the profi le of the cognitive eff ects of depression and antidepressant treatment, longitudinally across ill and euthymic states (encompassing successful and unsuccessful treatment) and across three diff erent, frequently used antidepressants.
With this approach, we reconcile inconsistencies in the published literature that have restricted our understanding of the cognitive eff ects of depression and antidepressant treatment, and the relevance of cognition as an endophenotype or as a treatment target. Until now, the question of whether cognitive impairments in depression are trait-like or state-like phenomena had not been answered conclusively. Here, we show a trait-like persistence of and absence of anti depressant treatment effi cacy for impairments in attention, response inhibition, verbal memory, infor mation processing, and decision speed, even in the context of clinical remission and independent of age. Furthermore, we show state-like improvement in the domains of cognitive fl exibility and executive function (here, measured in visuospatial planning and self-monitoring task). Although we cannot defi nitively say if improvement in executive function above that seen in healthy controls is due to benefi t from practice, placebo eff ects, or active treatment, our data for cognitive fl exibility suggest improvement caused by intact practice eff ects in this domain. By virtue of assessing a broad set of cognitive domains over the course of treatment in a large sample, our data overcome diffi culties of previous work that has produced inconsistent results, and clearly delineate which subsets of domains show more trait-like and which show more state-like impairments. Interestingly, the pattern of trait-like and state-like cognitive impairments is not directly indicative of cognitive load, which is consistent with previous studies. 11, 16 One area probed by our tasks with more traitlike impairments, 24 the orbitofrontal cortex, also shows trait-like abnormalities in activity during a functional imaging study of a mood challenge in the clinically remitted state of depression. 25 Perhaps tasks showing trait-like impairments probe an underlying persistent neural circuit dysfunction associated with depression.
Our objective test battery captured objective task-based cognitive impairments that persisted beyond improvement in subjective reports of impaired concentration. A poor correlation between subjective and objective measures of cognitive performance has long been recorded in depression, across diff erent assessment methods. 26 Subjective report (either broadly, or of concentration symptoms specifi cally) therefore provides a poor assessment of cognitive function in the setting of depression, where it can be aff ected by mood symptoms and self-evaluation biases. Additionally, poor subjective insight into cognitive accuracy is reported in healthy patients, in part due to expectancy eff ects, 27 and similarly might contribute to a poor correlation between subjective and objective assessment of cognition in depression. Our work emphasises the usefulness of objective cognitive measures in capturing the complete range of impairments associated with depression during acute episodes and upon remission.
Our study assessed the eff ects of three diff erent commonly prescribed antidepressants on cognitive impairments that occur in depression. All three antidepressants were prescribed according to standard clinical practice: two selective serotonin reuptake inhibitors (escitalopram and sertraline) and a serotoninnorepinephrine reuptake inhibitor (venlafaxine-XR). Cognitive change, however, does not diff er across treatment groups in any cognitive domain, including for those cognitive domains in which improvement was recorded at week 8. Therefore, if any true diff erence between treatment groups were to exist, it would have to have a very small eff ect size relative to the severity of cognitive impairment in patients, since our study is powered to detect changes with eff ect sizes greater than 0·009 (partial η², based on power analysis for repeated measures ANOVA examining time × remission status × treatment group eff ects), which is well below what is accepted as a small eff ect size (0·2-0·3). Consistent with this idea, only a small proportion of people show broad cognitive improvement in any treatment group (4·5%, based on the individual reliable change index analysis), and the average cognitive change in any treatment group is small compared with the total cognitive impairment in all domains (based on the group analysis). Interestingly, cortical activity during cognitive task performance (response inhibition) predicts outcome to venlafaxine-XR in a neuroimaging subsample from this study, 28 but cognitive performance itself does not change with venlafaxine treatment at the behavioural level.
Our analysis of individuals grouped by their course of cognitive symptoms shows that improvement in cognition rarely occurs in more than two cognitive domains in any individual. However, the small subgroup of patients (32 [4·5%] of all patients with depression) showing broader improvement across more cognitive domains also has later age of illness onset, although interestingly not a decrease in the number of lifetime depressive episodes. Furthermore, where improvement is recorded at the group level in cognitive fl exibility and executive function, greater improvement is associated with less clinical chronicity.
Several limitations of this study should be noted. Since the remitted group still has a small but still statistically signifi cant increase in symptoms after 8 weeks of treatment compared with healthy controls, we cannot rule out that complete elimination of symptoms might be necessary before cognitive dysfunction improves. Second, the 8-week treatment period is quite short, with sustained remission defi ned by a period of 8 weeks since last depressive episode in published literature. 23 Therefore, further studies assessing patients over longer periods of treatment will be important follow-up to the present fi ndings. Additionally, patients have a variable clinical history before entry into this study. Neither clinical history nor demographics predicted treatment response or diff ered across treatment groups in this study; 18 however, we cannot generalise our fi ndings here to patients earlier in their illness course without previous acute episodes or treatment history. Again, follow-up studies in this population might address whether or not cognitive impairment is less persistent earlier in illness or lifetime treatment course. Finally, although unlikely, cognitive dys function post-treatment might be related to medication use at week 8 in all patients (whereas cognitive impairments at baseline were due to the illness itself).
Future studies can address these limitations and analyse cognitive dysfunction as a distinct treatment target, aimed at improving long-term outcomes and addressing domains not already targeted by antidepressant medication. Antidepressants with alternative mechanisms to those tested in this study are available and can be assessed for effi cacy in targeting cognitive impairments in domains that we fi nd remain untreated using the medications tested here. Early studies of these medications have reported effi cacy for cognitive domains that we found to be unresponsive to selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor antidepressants used in this study. For example, 8 weeks of treatment with vortioxetine (a pharmacodynamically novel multimodal antidepressant that exerts eff ects across several neurotransmitter systems in addition to acting at serotonin receptors and inhibiting the serotonin transporter) was shown to improve verbal memory (measured using the Rey auditory verbal learning test), information processing (using simple reaction time), decision speed (using the trail-making test), and cognitive fl exibility (using Stroop) in adult patients with recurrent major depressive disorder. 4 Although cognitive fl exibility was improved by antidepressants in our study too, the fi rst three domains were not improved in our study of the eff ects of antidepressants and therefore might be domains where vortioxetine shows improved effi cacy for cognition. Adjunct lisdexamfetamine (a pharmacologically inactive prodrug of d-amphetamine currently approved for treatment of ADHD) was also shown to improve executive function in patients with mild depression above that reported with monotherapy with a con ventional antidepressant. 5 However, here we also found executive function to improve with selective serotonin reuptake inhibitor or serotonin-norepi nephrine reuptake inhibitor treatment. In future work, it will be important to examine whether adjunct lisdexamfetamine also improves function in the fi ve cognitive domains unaff ected by common antidepressant treatment in our study. Consistent with our fi ndings here, studies of these agents suggest that additional mechanisms besides those used by selective serotonin reuptake inhibitor or serotoninnorepinephrine re uptake inhibitor anti depressants are needed to target the cognitive impairments associated with depression. Finally, our fi nding that patients still benefi t from intact practice-related learning in some domains is also consistent with early evidence for the effi cacy of cognitive training approaches in depression.
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